We are transforming peptide drug manufacturing
rBIO is developing a proprietary manufacturing process and licensing platform designed to improve the economics of peptide drug production, beginning with insulin.
Insulin first.
Licensing-ready platform.
Global manufacturing potential.
The problem
Complex manufacturing drives high drug prices
Diabetes has reached epidemic levels, yet insulin cost and supply remain major global challenges. A key driver is the complexity, cost, and limited scalability of peptide-drug manufacturing.
rBIO is focused on solving the manufacturing problem behind drug pricing.
Our platform is designed to help partners:
Improve production efficiency
Reduce manufacturing complexity
Support more stable supply
Expand access to essential peptide drugs
Initial focus: insulin
rBIO is applying its proprietary manufacturing process first to insulin, one of the world’s most widely used peptide drugs.
The company has completed early development work and is preparing for its next major scale-up milestone.
Progress to date:
20L pilot work completed
Exploratory animal study completed
1,000L scale-up planned
Process being prepared for licensing
Platform
A proprietary process built for scale
rBIO’s platform combines proprietary process IP with deep biomanufacturing know-how to improve peptide-drug production output, beginning with insulin.
The goal is to complete scale-up, validate the process at larger scale, and license the platform to qualified strategic and regional manufacturing partners.
Licensing model
Designed for faster global adoption
rBIO’s licensing model allows qualified partners to manufacture essential peptide drugs more efficiently without requiring rBIO to directly own and operate manufacturing infrastructure.
This creates a capital-efficient path to scale, partner-driven commercialization, and broader global access.
We are building a process.
We are preparing it to scale.
We are licensing it for impact
